Predictive Value of Abnormal and Borderline Ankle-Brachial Index for Coronary Re-Intervention and Mortality in Patients with Coronary Artery Disease: An Observational Cohort Study

Sanghyun Ahn¹*, EunAh Jo¹*, Seung-Kee Min¹, Sangil Min¹, Jongwon Ha¹, Kyung Woo Park², and Kyoung-Bok Min³

¹Department of Surgery, Seoul National University Hospital, Seoul, ²Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul, ³Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea

Purpose: This study aimed to investigate the abnormal and borderline ABIs for predicting coronary re-intervention and mortality in patients with coronary artery disease (CAD).

Materials and Methods: Data from a previous study were obtained and used to investigate the prevalence of peripheral arterial disease among Korean patients with CAD (n=285) in 2010. All patients underwent follow-up coronary angiography as scheduled (asymptomatic: 2-, 5-, and 7-month intervals) or as clinically indicated (symptomatic).

Results: In total, 33 patients had an abnormal ABI (ab-ABI: <1.0 or >1.4), and 252 had a normal ABI (nl-ABI: 1.0≤ABI≤1.4). The mean follow-up was 47 months. The mortality was significantly higher in the ab-ABI group than in the nl-ABI group (18.2% vs. 6.7%, P=0.0233). MACEs were significantly more common in the ab-ABI group (60.6% vs. 34.5%, P=0.0036). Moreover, the ab-ABI group had a greater CAD progression than the nl-ABI group (48.5% vs. 31.3%, P=0.0496). The incidence of clinically indicated coronary re-intervention was significantly higher in the ab-ABI group than in the nl-ABI group (33.3% vs. 13.1%, P=0.0025). After adjusting for age, diabetes, dyslipidemia, dialysis, smoking, and obesity, the incidence of clinically indicated re-intervention was significantly higher in the ab-ABI group than in the nl-ABI group (HR, 2.80; 95% CI, 1.24 to 6.34).

Conclusion: Abnormal and borderline ABI significantly increased the incidence of clinically indicated coronary revascularization and all-cause mortality during a 4-year follow-up among patients with CAD. Hence, ABI could be used to stratify extremely high-risk patients with CAD who may require aggressive surveillance or treatment.

Key Words: Coronary artery disease, Ankle brachial index, Borderline, Coronary intervention, Peripheral arterial disease

Received March 2, 2020
Revised May 5, 2020
Accepted May 27, 2020

Corresponding author: Kyoung-Bok Min
Department of Preventive Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel: 82-2-2072-2817
Fax: 82-2-766-3975
E-mail: minkb@snu.ac.kr
https://orcid.org/0000-0001-9576-0093

*These authors contributed equally to this work.

Copyright © 2020, The Korean Society for Vascular Surgery
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Vasc Specialist Int 2020;36(2):89-95 • https://doi.org/10.5758/vsi.200012
INTRODUCTION

The ankle-brachial index (ABI), the ratio of ankle to arm systolic blood pressure, is a simple diagnostic test that is available in any primary care setting [1]. In a previous study, approximately 15.9% of patients with significant coronary artery disease (CAD) on coronary angiography (CAG) presented with an asymptomatic abnormal ABI (ab-ABI) [2]. Moreover, our previous study of a Korean population showed that 15% of patients with CAD had peripheral arterial disease (PAD) [3].

Several studies have shown that an ABI <0.90 is a marker of future cardiovascular risk and is a diagnostic criterion of PAD [4]. In addition, an ab-ABI is associated with a high incidence of adverse clinical outcomes and poor cardiovascular outcomes in patients who underwent drug-eluting stent implantation [5].

A borderline ABI (0.91 to 0.99) is not included in the conventional diagnostic criteria for PAD. However, it increases the incidence of PAD and leads to a poor long-term prognosis [6]. Furthermore, it is associated with poor short-term clinical outcomes after coronary artery interventions, which can be correlated with endothelial dysfunction [7-9]. Such important outcomes should be considered. However, long-term studies of the mortality and prognosis of CAD patients with an abnormal or borderline ABI have not been published to date.

Hence, this study aimed to investigate the significance of abnormal and borderline ABI in terms of mortality, coronary re-intervention, and disease progression (DP) during a follow-up period of 4 years in Korean patients with CAD.

MATERIALS AND METHODS

1) Study population

The current observational cohort study was performed using data from a previous study [3] to investigate the prevalence of PAD among patients with CAD in 2010. Patients who were diagnosed with CAD and who underwent CAG at least twice (n=285) were included in this study. However, CAD patients who underwent coronary artery graft bypass surgery were excluded. Data about mortality rates in December 2014 were provided by the Korea National Statistical Office (https://kostat.go.kr). All patients underwent follow-up CAG (either scheduled or clinically indicated).

The group was divided based on two categories: 1) normal ABI (nl-ABI): 1.0≤ABI≤1.4 and 2) ab-ABI, including PAD (ABI≤0.9), non-compressible (ABI>1.4), and borderline (0.90<ABI<1.00) [10,11]. Trained physician assistants measured ABI using a 10 to 20 cm sphygmanometer and a handheld Doppler (Hadeco®; Hadeco, Tokyo, Japan).

The endpoints included all-cause mortality, major adverse cardiac events (MACEs), DP, repeated revascularization (RR), and DP pattern (DPP).

The institutional review board of Seoul National University Hospital approved this study, and the need for informed consent was waived (H-1602-059-740).

2) Definitions

MACE was defined as the composite of death, myocardial infarction (MI), or stroke. DP was defined as stenosis >30% or occlusion of any coronary artery on the latest CAG. The indication for RR was stenosis >50% on CAG or stenosis <50% with a correlated symptom. CAG was performed when scheduled (asymptomatic: 2-, 5-, and 7-month intervals) or clinically indicated (symptomatic with correlation with MI or angina). To evaluate DP, the target lesion was defined as the vessel segment containing the initially treated (stented or percutaneous transluminal angioplasty) lesion. The target vessel was defined as any other segment in the same epicardial vessel or one of its side branches. A non-target vessel or other was defined as the epicardial coronary arteries, not including the target lesion [12]. Data on mortality rates until December 2014 were obtained from the Korean National Statistical Office.

3) Statistical analysis

The baseline characteristics of the participants, who were categorized according to ABI (ab-ABI: <1.0 or >1.4 vs. nl-ABI: 1.0≤ABI≤1.4)
Predictive Value of ABI for Coronary Re-Intervention and Mortality in CAD

versus nl-ABI: 1.0≤ABI≤1.4), were compared using the chi-square test. For the primary analysis of the association between ABI categories and health outcomes, we examined the proportion (%) of patients with ab-ABI and nl-ABI according to the incidence of MACE, DP, and RR and all-cause mortality during the follow-up period, and the possible association between them was determined using the chi-square test. The Kaplan–Meier curves were used to evaluate the cumulative hazard for RR in patients with ab-ABI and those with nl-ABI (Fig. 1). We conducted a multivariate Cox proportional hazards regression analysis of the health outcomes during the study period. The proportional hazards assumption for the model was confirmed. The hazard ratios (HRs) and 95% confidence intervals (CIs) for the incidence of MACE, DP, and RR and all-cause mortality in patients with ab-ABI and nl-ABI were evaluated. In the multivariate analyses, model 1 was adjusted for demographic variables (i.e., age and sex), and model 2 was further adjusted for cigarette smoking, body mass index, number of diseased vessels, and underlying disease. All analyses were performed using SAS 9.4 software (SAS Institute, Cary, NC, USA), and P-values <0.05 was considered statistically significant.

RESULTS

1) Demographic characteristics of the participants

Of 285 patients enrolled in this study, 33 (11.6%) had ab-ABI and 252 (88.4%) had nl-ABI. The mean follow-up was 47 months. The characteristics of the patients are shown in Table 1. The ab-ABI group had a significantly higher incidence of end-stage renal disease and three-vessel disease than the nl-ABI group. Half of the patients in the ab-ABI group had diabetes, and the intergroup difference was statistically significant.

2) Primary outcomes: all-cause mortality and incidence of MACE, DP, and RR

The all-cause mortality and incidence of MACE, DP, and RR were significantly higher in the ab-ABI group than in the nl-ABI group. The Kaplan–Meier curves were used to evaluate the cumulative hazard for RR in patients with ab-ABI and those with nl-ABI (Fig. 1). We conducted a multivariate Cox proportional hazards regression analysis of the health outcomes during the study period. The proportional hazards assumption for the model was confirmed. The hazard ratios (HRs) and 95% confidence intervals (CIs) for the incidence of MACE, DP, and RR and all-cause mortality in patients with ab-ABI and nl-ABI were evaluated. In the multivariate analyses, model 1 was adjusted for demographic variables (i.e., age and sex), and model 2 was further adjusted for cigarette smoking, body mass index, number of diseased vessels, and underlying disease. All analyses were performed using SAS 9.4 software (SAS Institute, Cary, NC, USA), and P-values <0.05 was considered statistically significant.

Table 1. Baseline characteristics of the participants according to ABI categories

| Characteristic | Patients with ab-ABI (n=33) | Patients with nl-ABI (n=252) | P-valueb |
|---------------|-----------------------------|-----------------------------|----------|
| Age (y)       |                             |                             |          |
| 50-59         | 5 (15.2)                    | 63 (25.0)                   | 0.1922   |
| 60-69         | 12 (36.4)                   | 108 (42.9)                  |          |
| 70-79         | 13 (39.4)                   | 72 (28.6)                   |          |
| ≥80           | 3 (9.1)                     | 9 (3.6)                     |          |
| Sex           |                             |                             |          |
| Male          | 21 (63.6)                   | 187 (74.2)                  | 0.1985   |
| Female        | 12 (36.4)                   | 65 (25.8)                   |          |
| Cigarette smoking |                        |                             |          |
| No            | 15 (45.5)                   | 129 (51.2)                  | 0.5354   |
| Yes           | 18 (54.5)                   | 123 (48.8)                  |          |
| BMI (kg/m²)   |                             |                             |          |
| <25           | 16 (48.5)                   | 112 (44.4)                  | 0.6608   |
| ≥25           | 17 (51.5)                   | 140 (55.6)                  |          |
| Number of diseased vessels |                       |                             |          |
| 1             | 6 (18.2)                    | 98 (38.9)                   | 0.0234   |
| 2             | 10 (30.3)                   | 78 (31.0)                   |          |
| 3             | 17 (51.5)                   | 76 (30.2)                   |          |
| Underlying disease |                       |                             |          |
| Diabetes      | 17 (51.5)                   | 83 (32.9)                   | 0.0355   |
| Dyslipidemia  | 25 (75.8)                   | 160 (63.5)                  | 0.1650   |
| Hemodialysis  | 3 (9.1)                     | 5 (2.0)                     | 0.0201   |

Values are presented as number (%). ABI, ankle-brachial index; ab-ABI, abnormal ABI; nl-ABI, normal ABI; BMI, body mass index.

Table 2. Health outcomes of participants according to ABI categories during the follow-up period

| Health outcomes | Patients with ab-ABI (n=33) | Patients with nl-ABI (n=252) | P-valueb |
|-----------------|-----------------------------|-----------------------------|----------|
| MACEc           |                             |                             |          |
| Yes             | 20 (60.6)                   | 87 (34.5)                   | 0.0036   |
| No              | 13 (39.4)                   | 165 (65.5)                  |          |
| Disease progressiond |                       |                             |          |
| Yes             | 16 (48.5)                   | 79 (31.3)                   | 0.0496   |
| No              | 17 (51.5)                   | 173 (68.7)                  |          |
| Repeated revascularizatione |                   |                             |          |
| Yes             | 11 (33.3)                   | 33 (13.1)                   | 0.0025   |
| No              | 22 (66.7)                   | 219 (86.9)                  |          |
| All-cause mortality |                       |                             |          |
| Yes             | 6 (18.2)                    | 17 (6.7)                    | 0.0233   |
| No              | 27 (81.8)                   | 235 (93.3)                  |          |

Values are presented as number (%). ABI, ankle-brachial index; ab-ABI, abnormal ABI; nl-ABI, normal ABI; MACE, major adverse cardiac events.

aABI categories were defined as ab-ABI (<1.0 or >1.4) and nl-ABI (1.0≤ABI≤1.4). P-value was determined using the chi-square test. MACE included disease progression, repeated revascularization, and all-cause mortality. Disease progression was defined as stenosis >30% or occlusion of any coronary artery on the latest coronary angiography. Repeated revascularization was defined as stenosis >50% on coronary angiography or stenosis <50% with a correlated symptom.
the nl-ABI group (Table 2). All-cause mortality and MACE occurred in 6 (18.2%) and 20 (60.6%) patients in the ab-ABI group and in 17 (6.7%) and 87 (34.5%) patients in the nl-ABI group (P=0.0233, P=0.0036) during the 4-year follow-up period. The all-cause rate and incidence rate of MACE was 2 to 3 times higher in the ab-ABI group than in the nl-ABI group. CAD progression was more common in the ab-ABI group (n=16, 48.5%) than in the nl-ABI group (n=79, 31.3%; P=0.0496). The incidence of clinically indicated coronary re-intervention was significantly higher in the ab-ABI group (n=11, 33.3%) than in the nl-ABI group (33, 13.1%; P=0.0025).

3) DP according to Scheduled or Clinically Indicated CAG

The overall DP based on scheduled and clinically indicated CAG was higher in the ab-ABI group than in the nl-ABI group. DP requiring RR was significantly higher in patients with ab-ABI and clinically indicated CAG, but not for those with scheduled CAG (Fig. 1). This cumulative incidence was nearly three times higher in patients with ab-ABI than in

Table 3. Hazard ratio (95% confidence intervals) for health outcomes according to ABI categories

| Health outcomes                  | Unadjusted model | Adjusted modela |
|----------------------------------|------------------|-----------------|
|                                  | Model 1          | Model 2         |
| MACEb                            |                  |                 |
| nl-ABI                           | Reference        | Reference       |
| ab-ABI                           | 1.99 (1.22-3.24) | 1.74 (1.06-2.87)| 1.50 (0.89-2.50) |
| Disease progressionc              | Reference        | Reference       |
| nl-ABI                           | Reference        | Reference       |
| ab-ABI                           | 1.54 (0.89-2.66) | 1.44 (0.83-2.51)| 1.19 (0.67-2.15) |
| Repeated revascularizationd       | Reference        | Reference       |
| nl-ABI                           | Reference        | Reference       |
| ab-ABI                           | 2.53 (1.25-5.12) | 2.53 (1.20-5.34)| 2.80 (1.24-6.34) |
| All-cause mortality               | Reference        | Reference       |
| nl-ABI                           | Reference        | Reference       |
| ab-ABI                           | 2.98 (1.17-7.55) | 2.53 (0.98-6.50)| 2.24 (0.82-6.09) |

ABI, ankle-brachial index; MACE, major adverse cardiac events; nl-ABI, normal ABI; ab-ABI, abnormal ABI.

aABI categories were defined as ab-ABI (<1.0 or >1.4) and nl-ABI (1.0≤ABI≤1.4).
aModel 1 was adjusted for age and sex and model 2 was further adjusted for cigarette smoking, body mass index, number of diseased vessels, and underlying disease.
bMACE included disease progression, repeated revascularization, and all-cause mortality.
cDisease progression was defined as stenosis >30% or occlusion of any coronary artery that has newly appeared on the latest coronary angiography.
dRepeated revascularization was identified as stenosis >50% on coronary angiography or stenosis <50% with a correlated symptom.

Fig. 2. Comparison of ankle-brachial index (ABI) cutoff values of 1.0 and 0.9 using the area under the curve (AUC). ROC, receiver operating characteristic.
those with nl-ABI. The most common disease pattern was
in the target lesion (58.3% in the ab-ABI group, 50% in
the nl-ABI group), and there was no intergroup difference
(P=0.577).

4) Risk factors for RR

Using the Cox proportional hazards model for clinically
indicated RR after adjusting for age and sex (model 1) and
model 1 plus diabetes, dyslipidemia, dialysis, smoking, obe-
sity, and number of affected vessels, the incidence of clin-
ically indicated re-intervention was significantly higher in
the ab-ABI group than in the nl-ABI group (HR, 2.80; 95% CI,
1.24 to 6.34). In summary, the ABI remained an inde-
pendent predictor of RR (Table 3).

The significance of ABI cutoff values of 1.0 and 0.9 was
compared using the area under the curve (Fig. 2). The value
measures a test’s capability to accurately classify those with
and without the disease. The area under the receiver op-
erating characteristics curve for an ABI of 1.0 was 0.8264,
and that for an ABI of 0.9, which is an excellent discrimina-
tion value for predicting RR was, 0.7988.

DISCUSSION

The current study investigated the significance of an ab-
ABI (including a borderline ABI) with respect to mortality,
coronary re-intervention, and DPP during a follow-up pe-
riod of 4 years in patients with CAD. CAD patients with ab-
ABI had higher rates of all-cause mortality (18.2% vs. 6.7%,
P=0.0233) and clinically indicated coronary RR (33.3% vs.
13.1%, P=0.0025) than those with nl-ABI. The most common disease pattern was
in the target lesion (58.3% in the ab-ABI group, 50% in
the nl-ABI group), and there was no intergroup difference
(P=0.577).

An ab-ABI (including low and borderline values) sig-
ificantly increased the incidence of clinically indicated
coronary RR (HR, 2.80; 95% CI, 1.24 to 6.34) and all-cause
mortality (18.2%) during the 4-year follow-up in patients
with CAD. Hence, ABI could be used to further stratify
extremely high-risk patients with CAD who may require ag-

CONCLUSION

An ab-ABI (including low and borderline values) sig-
ificantly increased the incidence of clinically indicated
coronary RR (HR, 2.80; 95% CI, 1.24 to 6.34) and all-cause
mortality (18.2%) during the 4-year follow-up in patients
with CAD. Hence, ABI could be used to further stratify
extremely high-risk patients with CAD who may require ag-
progressive surveillance or further treatment.

**CONFLICTS OF INTEREST**

The authors have nothing to disclose.

**ORCID**

Sanghyun Ahn  
https://orcid.org/0000-0003-2094-3586  
EunAh Jo  
https://orcid.org/0000-0002-9324-4877  
Seung-Kee Min  
https://orcid.org/0000-0002-1433-2562  
Sangil Min  
https://orcid.org/0000-0002-0688-0278  
Jongwon Ha  
https://orcid.org/0000-0003-2285-3517  
Kyung Woo Park  
https://orcid.org/0000-0003-2432-4432  
Kyoung-Bok Min  
https://orcid.org/0000-0001-9576-0093

**AUTHOR CONTRIBUTIONS**

Concept and design: SA. Analysis and interpretation: EAJ. Data collection: SA, KWP. Writing the article: EAJ. Critical revision of the article: SKM, SM, JH. Final approval of the article: SKM. Statistical analysis: KBM. Obtained funding: none. Overall responsibility: SA.

**REFERENCES**

1) Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 1999;19:538-545.

2) Lee JY, Lee SW, Lee WS, Han S, Park YK, Kwon CH, et al. Prevalence and clinical implications of newly revealed, asymptomatic abnormal ankle-brachial index in patients with significant coronary artery disease. JACC Cardiovasc Interv 2013;6:1303-1313.

3) Ahn S, Park YJ, Min SI, Kim SY, Ha J, Kim SJ, et al. High prevalence of peripheral arterial disease in Korean patients with coronary or cerebrovascular disease. J Korean Med Sci 2012;27:625-629.

4) Doobay AV, Anand SS. Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review. Arterioscler Thromb Vasc Biol 2005;25:1463-1469.

5) Kim HL, Seo JB, Chung WY, Zo JH, Kim MA, Kim SH. Prognostic value of the ankle-brachial index in patients undergoing drug-eluting stent implantation. J Atheroscler Thromb 2015;22:27-37.

6) Natsuaki C, Inoguchi T, Maeda Y, Yamada T, Sasaki S, Sonoda N, et al. Association of borderline ankle-brachial index with mortality and the incidence of peripheral artery disease in diabetic patients. Atherosclerosis 2014;234:360-365.

7) Ribera A, Ferreira-González I, Marsal JR, Cascant P, Pernyamey-Miralda G, Abdul-Jawad O, et al. Prognostic value of an abnormal ankle-brachial index in patients receiving drug-eluting stents. Am J Cardiol 2011;108:1225-1231.

8) Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, et al. Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008;300:197-208.

9) Kajikawa M, Maruhashi T, Iwamoto Y, Iwamoto A, Matsumoto T, Hidaka T, et al. Borderline ankle-brachial index value of 0.91-0.99 is associated with endothelial dysfunction. Circ J 2014;78:1740-1745.

10) Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. Editor’s Choice - 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2018;55:305-368.

11) Stoner MC, Calligaro KD, Chaer RA, Dietzek AM, Farber A, Guzman RJ, et al. Reporting standards of the Society for Vascular Surgery for endovascular treatment of chronic lower extremity peripheral artery disease. J Vasc Surg 2016;64:e21-e21.

12) Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol 2015;66:403-469.

13) Hashizume N, Miura T, Miyashita Y, Motoki H, Ebisawa S, Izawa A, et al. Prognostic value of ankle-brachial index in patients undergoing percu-
taneous coronary intervention: in-hospital and 1-year outcomes from the SHINANO Registry. Angiology 2017;68:884-892.

14) Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017;69:e71-e126.

15) Zheng ZJ, Sharrett AR, Chambless LE, Rosamond WD, Nieto FJ, Sheps DS, et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 1997;131:115-125.

16) Calling S, Ji J, Sundquist J, Sundquist K, Zöller B. Shared and non-shared familial susceptibility of coronary heart disease, ischemic stroke, peripheral artery disease and aortic disease. Int J Cardiol 2013;168:2844-2850.

17) Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-189.

18) Vu TH, Stamler J, Liu K, McDermott MM, Lloyd-Jones DM, Pirzada A, et al. Prospective relationship of low cardiovascular risk factor profile at younger ages to ankle-brachial index: 39-year follow-up--the Chicago Healthy Aging Study. J Am Heart Assoc 2012;1:e001545.

19) Tsivgoulis G, Bogiatzi C, Heliopoulos I, Vadikolias K, Boutati E, Tsakaldimi S, et al. Low ankle-brachial index predicts early risk of recurrent stroke in patients with acute cerebral ischemia. Atherosclerosis 2012;220:407-412.

20) Hong JB, Leonards CO, Endres M, Siegerink B, Liman TG. Ankle-brachial index and recurrent stroke risk: meta-analysis. Stroke 2016;47:317-322.

21) Manzano JJ, De Silva DA, Pascual JL, Chang HM, Wong MC, Chen CP. Associations of ankle-brachial index (ABI) with cerebral arterial disease and vascular events following ischemic stroke. Atherosclerosis 2012;223:219-222.

22) Jones WS, Patel MR, Rockman CB, Guo Y, Adelman M, Riles T, et al. Association of the ankle-brachial index with history of myocardial infarction and stroke. Am Heart J 2014;167:499-505.